Premium
Number of negative lymph nodes as a prognostic factor in esophageal squamous cell carcinoma
Author(s) -
Ma Mingquan,
Tang Peng,
Jiang Hongjing,
Gong Lei,
Duan Xiaofeng,
Shang Xiaobin,
Yu Zhentao
Publication year - 2017
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.12567
Subject(s) - medicine , stage (stratigraphy) , carcinoma , oncology , lymph , lymphadenectomy , multivariate analysis , gastroenterology , survival rate , esophagus , survival analysis , metastasis , esophageal cancer , t stage , lymph node , pathology , cancer , paleontology , biology
The aim of this study is to investigate the number of negative lymph nodes (NLNs) as a prognostic factor for survival in patients with resected esophageal squamous cell carcinoma. Methods A total of 381 esophageal squamous cell carcinoma patients who had underwent surgical resection as the primary treatment was enrolled into this retrospective study. The impact of number of NLNs on patient's overall survival was assessed and compared with the factors among the current tumor‐nodes‐metastasis (TNM) staging system. Results The number of NLNs was closely related to the overall survival, and the 5‐year survival rate was 45.4% for number of NLNs of >20 (142 cases) and 26.4% for NLNs ≤ 20 (239 cases) ( P = 0.001). In multivariate survival analysis, the number of NLNs remained an independent prognostic factor ( P = 0.002) as did the other current TNM factors. For subgroup analysis, the predictive value of number of NLNs was significant in patients with T3 or T4 disease ( P = 0.001) and patients with N1 and N2–3 disease ( P = 0.025, 0.043), but not in patients with T1 or T2 disease or patients with N0 disease. Conclusions The number of NLNs, which represents the extent of lymphadenectomy for esophageal squamous cell carcinoma, could impact the overall survival of patients with resected esophageal squamous cell carcinoma, especially among those with nodal‐positive disease and advanced T‐stage tumor.